These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 27420584

  • 1. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
    Zhu N, Zhao X, Xiang Y, Ye S, Huang J, Hu W, Lv L, Zeng C.
    Int J Cardiol; 2016 Oct 15; 221():587-96. PubMed ID: 27420584
    [Abstract] [Full Text] [Related]

  • 2. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R, Wei Z, Zhu D, Fu N, Wang C, Yin S, Liang Y, Xing J, Wang X, Wang Y.
    Pulm Pharmacol Ther; 2018 Feb 15; 48():124-135. PubMed ID: 29133079
    [Abstract] [Full Text] [Related]

  • 3. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
    Liu J, Fang G, Lan C, Qiu C, Yao L, Zhang Q, Hu J, Zhang Y, Yang Y, Zhang Y.
    Drug Des Devel Ther; 2024 Feb 15; 18():767-780. PubMed ID: 38495631
    [Abstract] [Full Text] [Related]

  • 4. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C, Shi W, Feng W, Zhu Y, Wang J, Li S, Yan X, Wang Q, Zhang Q, Chai L, Li C, Liu P, Li M.
    Life Sci; 2018 Sep 01; 208():87-95. PubMed ID: 30009823
    [Abstract] [Full Text] [Related]

  • 5. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
    Cai C, Xiang Y, Wu Y, Zhu N, Zhao H, Xu J, Lin W, Zeng C.
    Mol Med Rep; 2019 Dec 01; 20(6):4984-4992. PubMed ID: 31702810
    [Abstract] [Full Text] [Related]

  • 6. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

  • 7. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
    He RL, Wu ZJ, Liu XR, Gui LX, Wang RX, Lin MJ.
    Cell Physiol Biochem; 2018 Nov 25; 49(1):172-189. PubMed ID: 30134231
    [Abstract] [Full Text] [Related]

  • 8. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.
    Cardiovasc Res; 2013 Jul 01; 99(1):35-43. PubMed ID: 23631839
    [Abstract] [Full Text] [Related]

  • 9. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH, Park BK, Oh KS, Yi KY, Lim CJ, Seo HW, Lee BH.
    Int Immunopharmacol; 2016 Nov 01; 40():196-202. PubMed ID: 27611861
    [Abstract] [Full Text] [Related]

  • 10. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
    Shi W, Zhai C, Feng W, Wang J, Zhu Y, Li S, Wang Q, Zhang Q, Yan X, Chai L, Liu P, Chen Y, Li M.
    Life Sci; 2018 Oct 01; 210():140-149. PubMed ID: 30179628
    [Abstract] [Full Text] [Related]

  • 11. Aloperine protects pulmonary hypertension via triggering PPARγ signaling and inhibiting calcium regulatory pathway in pulmonary arterial smooth muscle cells.
    Shan X, Gegentuya, Wang J, Feng H, Zhang Z, Zheng Q, Zhang Q, Yang K, Wang J, Xu L.
    Am J Physiol Cell Physiol; 2023 Oct 01; 325(4):C1058-C1072. PubMed ID: 37661916
    [Abstract] [Full Text] [Related]

  • 12. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X, Chen C, Dong W.
    J Vasc Surg; 2016 Nov 01; 64(5):1468-1477. PubMed ID: 26527422
    [Abstract] [Full Text] [Related]

  • 13. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
    Yang JM, Zhou R, Zhang M, Tan HR, Yu JQ.
    Molecules; 2018 May 26; 23(6):. PubMed ID: 29861433
    [Abstract] [Full Text] [Related]

  • 14. Thymoquinone suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation, migration and neointimal formation.
    Zhu N, Xiang Y, Zhao X, Cai C, Chen H, Jiang W, Wang Y, Zeng C.
    J Cell Mol Med; 2019 Dec 26; 23(12):8482-8492. PubMed ID: 31638340
    [Abstract] [Full Text] [Related]

  • 15. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
    Chen YC, Yuan TY, Zhang HF, Wang DS, Yan Y, Niu ZR, Lin YH, Fang LH, Du GH.
    Acta Pharmacol Sin; 2016 Jun 26; 37(6):772-82. PubMed ID: 27180980
    [Abstract] [Full Text] [Related]

  • 16. AOS ameliorates monocrotaline-induced pulmonary hypertension by restraining the activation of P-selectin/p38MAPK/NF-κB pathway in rats.
    Hu Y, Feng Z, Feng W, Hu T, Guan H, Mao Y.
    Biomed Pharmacother; 2019 Jan 26; 109():1319-1326. PubMed ID: 30551382
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y, Yu M, Xu J, He M, Wang H, Kong H, Xie W.
    BMC Pulm Med; 2018 Aug 07; 18(1):130. PubMed ID: 30086741
    [Abstract] [Full Text] [Related]

  • 18. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G, Wang X, Li Y, He L.
    Stem Cell Res Ther; 2017 Feb 10; 8(1):34. PubMed ID: 28187784
    [Abstract] [Full Text] [Related]

  • 19. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension.
    Chen X, Yu X, Lian G, Tang H, Yan Y, Gao G, Huang B, Luo L, Xie L.
    Biomed Pharmacother; 2024 May 10; 174():116505. PubMed ID: 38574614
    [Abstract] [Full Text] [Related]

  • 20. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP, Dai ZK, Huang CH, Yeh JL, Wu BN, Wu JR, Chen IJ.
    Kaohsiung J Med Sci; 2014 Jun 10; 30(6):267-78. PubMed ID: 24835346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.